CR20230438A - Inhibidores heterocíclicos de la cinasa rip1 - Google Patents
Inhibidores heterocíclicos de la cinasa rip1Info
- Publication number
- CR20230438A CR20230438A CR20230438A CR20230438A CR20230438A CR 20230438 A CR20230438 A CR 20230438A CR 20230438 A CR20230438 A CR 20230438A CR 20230438 A CR20230438 A CR 20230438A CR 20230438 A CR20230438 A CR 20230438A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heterocyclic
- kinase inhibitors
- rip1 kinase
- compounds
- kinase
- Prior art date
Links
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 101150040948 RIP1 gene Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 101000971351 Homo sapiens KRR1 small subunit processome component homolog Proteins 0.000 abstract 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
En la presente descripción se describen compuestos inhibidores de cinasa, tales como compuestos inhibidores de proteína 1 cinasa que interactúa con el receptor (RIP1), de la Fórmula (I), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas, y/o combinaciones descritas pueden usarse para tratar o prevenir una enfermedad o afección asociada a cinasas, particularmente una enfermedad o afección asociada a RIP 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163159970P | 2021-03-11 | 2021-03-11 | |
PCT/US2022/019744 WO2022192533A1 (en) | 2021-03-11 | 2022-03-10 | Heterocyclic rip1 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230438A true CR20230438A (es) | 2024-01-16 |
Family
ID=81327717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230438A CR20230438A (es) | 2021-03-11 | 2022-03-10 | Inhibidores heterocíclicos de la cinasa rip1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220296608A1 (es) |
EP (1) | EP4304713A1 (es) |
JP (1) | JP2024509466A (es) |
KR (1) | KR20230144575A (es) |
CN (1) | CN117083270A (es) |
AR (1) | AR125587A1 (es) |
AU (1) | AU2022232927A1 (es) |
BR (1) | BR112023018167A2 (es) |
CA (1) | CA3211778A1 (es) |
CL (1) | CL2023002704A1 (es) |
CO (1) | CO2023012077A2 (es) |
CR (1) | CR20230438A (es) |
DO (1) | DOP2023000186A (es) |
EC (1) | ECSP23068893A (es) |
IL (1) | IL305456A (es) |
PE (1) | PE20240237A1 (es) |
TW (1) | TW202300490A (es) |
WO (1) | WO2022192533A1 (es) |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
CA2031376A1 (en) | 1989-12-04 | 1991-06-05 | Bahram Farhadieh | Single layer transdermal drug administration system |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
WO1993011938A1 (en) | 1991-12-18 | 1993-06-24 | Minnesota Mining And Manufacturing Company | Multilayered barrier structures |
ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
US8922322B2 (en) * | 2012-08-31 | 2014-12-30 | Delta Electronics, Inc. | Combined structure of hollow bobbin and conductive sheet, hollow bobbin, and conductive sheet |
TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
RU2017109122A (ru) * | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
AU2016287581B2 (en) * | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
CR20180413A (es) * | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
JP7045526B2 (ja) * | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Rip1キナーゼを阻害する複素環状アミド及びその使用 |
CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
US11479543B2 (en) * | 2019-09-06 | 2022-10-25 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 kinase inhibitors |
CA3162605A1 (en) * | 2019-11-26 | 2021-06-03 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
-
2022
- 2022-03-02 TW TW111107595A patent/TW202300490A/zh unknown
- 2022-03-02 AR ARP220100461A patent/AR125587A1/es unknown
- 2022-03-10 KR KR1020237030350A patent/KR20230144575A/ko active Search and Examination
- 2022-03-10 US US17/691,596 patent/US20220296608A1/en active Pending
- 2022-03-10 PE PE2023002567A patent/PE20240237A1/es unknown
- 2022-03-10 CA CA3211778A patent/CA3211778A1/en active Pending
- 2022-03-10 CR CR20230438A patent/CR20230438A/es unknown
- 2022-03-10 JP JP2023555403A patent/JP2024509466A/ja active Pending
- 2022-03-10 WO PCT/US2022/019744 patent/WO2022192533A1/en active Application Filing
- 2022-03-10 IL IL305456A patent/IL305456A/en unknown
- 2022-03-10 CN CN202280020689.7A patent/CN117083270A/zh active Pending
- 2022-03-10 AU AU2022232927A patent/AU2022232927A1/en active Pending
- 2022-03-10 EP EP22714650.3A patent/EP4304713A1/en active Pending
- 2022-03-10 BR BR112023018167A patent/BR112023018167A2/pt unknown
-
2023
- 2023-09-11 CL CL2023002704A patent/CL2023002704A1/es unknown
- 2023-09-11 DO DO2023000186A patent/DOP2023000186A/es unknown
- 2023-09-11 EC ECSENADI202368893A patent/ECSP23068893A/es unknown
- 2023-09-12 CO CONC2023/0012077A patent/CO2023012077A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20240237A1 (es) | 2024-02-16 |
JP2024509466A (ja) | 2024-03-01 |
CO2023012077A2 (es) | 2024-01-15 |
ECSP23068893A (es) | 2023-10-31 |
AR125587A1 (es) | 2023-08-02 |
KR20230144575A (ko) | 2023-10-16 |
TW202300490A (zh) | 2023-01-01 |
US20220296608A1 (en) | 2022-09-22 |
BR112023018167A2 (pt) | 2023-10-31 |
DOP2023000186A (es) | 2023-11-30 |
WO2022192533A1 (en) | 2022-09-15 |
CA3211778A1 (en) | 2022-09-15 |
IL305456A (en) | 2023-10-01 |
CL2023002704A1 (es) | 2024-03-22 |
EP4304713A1 (en) | 2024-01-17 |
CN117083270A (zh) | 2023-11-17 |
AU2022232927A1 (en) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002719A (es) | Inhibidores heterociclicos de la quinasa rip1. | |
PH12020551847A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
JOP20220246A1 (ar) | مثبطات rip1k | |
MX2020011622A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos. | |
MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
NO20061743L (no) | Kinazolinderivater | |
JOP20220056A1 (ar) | مركبات rip1 تثبيطية وطرق عملها واستخدامها | |
MX2009004746A (es) | Derivados de 1,2,4-triazol como inhibidores del receptor sigma. | |
NO20066081L (no) | Kinazolinderivater som erbB-reseptortyrosinkinaser | |
MY148107A (en) | Kinase inhibitor | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
MX2009005795A (es) | Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona. | |
TNSN08020A1 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
WO2007108947A3 (en) | Nitrofuran compounds for the treatment of cancer and angiogenesis | |
ECSP22097749A (es) | Inhibidores de ripk1 | |
CR20230438A (es) | Inhibidores heterocíclicos de la cinasa rip1 | |
AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 |